RGEN
RepligenยทNASDAQ
--
--(--)
--
--(--)
RGEN Profile
Repligen Corporation
A life sciences company focused on bioprocessing technology leadership
41 Seyon Street
, Bldg. 1
, Suite 100
, Waltham
, MA 02453
--
Repligen Corporation is a leader in supplying key biopharmaceutical products. The protein A produced by the company provides long-term supply, long-term contracts for important life science research companies, and is also sold directly to end users in the pharmaceutical processing chain. The company provides professional biological research and development products to SecreFlo's latest drug, which has submitted an application to the US Food and Drug Administration and has received priority testing, and the company has submitted a marketing authorization to the European drug regulatory agency. SecreFlo is a company that develops new imaging agents for synthetic human hormone drugs for the diagnosis of pancreatitis and a variety of potential pancreatic diseases. The company conducts two early research projects on rare diseases of the central nervous system, Friedrich's dyskinesia and spinal muscular atrophy have entered the first phase of clinical trials. In addition, the company has obtained an additional license for intellectual property from Bristol-Myers Squibb, the company's patent rights for the real-price sale of the drug abatacept in the United States. The company was established in May 1981.
